Propylthiouracil and thiamazole do not alter in vitro neutrophil oxidative burst

Metabolism. 2005 Mar;54(3):300-5. doi: 10.1016/j.metabol.2004.09.009.

Abstract

Propylthiouracil and thiamazole are thionamides used in the treatment of hyperthyroidism. In addition to reducing thyroid hormone synthesis, these drugs have other activities that improve the hypermetabolic state of the patients as well as adverse and toxic effects. The capacity of these 2 drugs to interfere with the production of reactive oxygen species of human neutrophils exposed in vitro to these drugs was evaluated. The production of reactive oxygen species was assessed by chemiluminescence assays and the cells were stimulated with zymosan particles opsonized with a pool of normal human serum. No alteration was found in the chemiluminescence response of treated human neutrophils when compared to controls. The results show that these drugs, at the studied concentrations and with the experimental approach used, have no direct effect on the production of oxidative burst of neutrophils. We conclude that if these drugs have any action on the oxidative metabolism of neutrophils these might include some metabolization steps that do not take place in this in vitro model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites / pharmacology
  • Antithyroid Agents / pharmacology*
  • Humans
  • In Vitro Techniques
  • Infant, Newborn
  • Kinetics
  • Luminescent Measurements
  • Luminol
  • Methimazole / pharmacology*
  • Propylthiouracil / pharmacology*
  • Respiratory Burst / drug effects*

Substances

  • Antimetabolites
  • Antithyroid Agents
  • Methimazole
  • Luminol
  • Propylthiouracil